Patent · US Active

Long acting insulin composition

US9265723B2 · kind B2 · utility

7Cited by

14References

50Claims

0Family size

Assignee

Sanofi-Aventis Deutschland GMBH · DE

Inventors

Kennett Sprogoe · Greve Strand, DK
Felix Cleemann · Mainz, DE
Ulrich Hersel · Heidelberg, DE
Silvia Kaden-Vagt · Heidelberg, DE
Torben Lessmann · Neustadt an der Weinstraße, DE
Harald Rau · Würzburg, DE
Thomas Wegge · Heidelberg, DE

Key dates

Filing date	Jul 30, 2010
Grant date	Feb 23, 2016
Priority date	—
Expiry date	Jul 30, 2030

Classification

Technology area (CPC Y)Emerging Cross-Sectional Technologies
CPC primaryY10T428/13
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

The present invention relates to a pharmaceutical composition comprising an insulin compound in a concentration that is sufficient to maintain a therapeutically effective level of the insulin compound in blood plasma for at least 3 days characterized by having a pharmacokinetic profile in vivo with substantially no burst of the insulin compound. The present invention further relates to the use of an insulin compound for preparing said pharmaceutical composition as well as a kit of parts comprising said pharmaceutical composition.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.